Long-Term Toxicity Monitoring via Electronic Patient-Reported Outcomes in Patients Receiving Chemotherapy
- 1 December 2007
- journal article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (34) , 5374-5380
- https://doi.org/10.1200/jco.2007.11.2243
Abstract
Purpose In cancer treatment trials, clinicians traditionally report patient toxicity symptoms. Alternatively, patients could provide this information directly. Patients and Methods The Common Terminology Criteria for Adverse Events (CTCAE) is the mandated instrument for tracking patient toxicity symptoms in National Cancer Institute (NCI)-sponsored cancer treatment trials. We adapted CTCAE symptom items into patient language and uploaded these to an online platform. Lung cancer outpatients receiving chemotherapy were invited to self-report selected symptoms at visits via waiting area computers or optional home access. Symptom reports were printed for nurses at visits, but no instructions were given with regard to use of this information. Results From June 2005 through March 2006, 125 patients were invited to participate, and 107 chose to enroll. Mean length of participation was 42 weeks (range, 1 to 71 weeks), by which time 35% died. The average number of clinic visits was 12 (range, 1 to 40 visits). At each consecutive visit, most patients (mean, 78%) logged in without significant attrition. Reasons for failure to log in included having no reminder and having inadequate time. Although 76% of enrollees had home computers, only 15% self-reported from home. Satisfaction with the system was high (90%), but only 51% felt communication was improved. All participating nurses understood the reports and felt this information was useful for clinical decisions, documentation, and discussions. However, only one of seven nurses discussed reports with patients frequently, with insufficient time being the most common barrier to discussions. Conclusion Online patient self-reporting is a feasible long-term strategy for toxicity symptom monitoring during chemotherapy, even among patients with advanced cancer and high symptom burdens. However, without explicit reminders and clinician feedback, patients demonstrated limited voluntary interest in self-reporting between visits.Keywords
This publication has 18 references indexed in Scilit:
- Clinical significance of patient-reported questionnaire data: another step toward consensusPublished by Elsevier ,2005
- Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labelsControlled Clinical Trials, 2004
- Feasibility of docetaxel, epirubicin, and capecitabine (TEX) plus pegfilgrastim as neoadjuvant treatment for primary breast cancer: A pilot studJournal of Clinical Oncology, 2004
- Patient reported outcomes as endpoints in medical researchStatistical Methods in Medical Research, 2004
- Assessment of patient‐reported outcomes in clinical trials: the example of health‐related quality of lifeFundamental & Clinical Pharmacology, 2004
- Incorporating the Patient's Perspective into Drug Development and Communication: An Ad Hoc Task Force Report of the Patient-Reported Outcomes (PRO) Harmonization Group Meeting at the Food and Drug Administration, February 16, 2001Value in Health, 2003
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003
- The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretationHealth and Quality of Life Outcomes, 2003
- The Regulation of Patient-Reported Outcome Claims: Need for a Flexible StandardValue in Health, 2002
- Patient-re ported complications and follow-up treatment after radical prostatectomy: The national medicare experience: 1988–1990 (updated June 1993)Urology, 1993